BERG is a clinical stage biopharmaceutical company that uses artificial intelligence to map disease and identify treatment candidates across oncology, neurology and rare diseases. Specifically, BERG identifies critical biomarkers that can accelerate the discovery and development of treatments aimed at the most promising therapeutic targets and pathways. Using its patented Interrogative Biology® AI platform, the Company has developed a robust pipeline of first-in-class product candidates and diagnostics that have the potential to improve patient lives.

BERG are proud supporters of the AI Applications in Biopharma Summit

Sessions

DAY 1 / ‏‏‎ ‎

09:00 AM - 09:40 AM
Plenary View Session
Description

Executive Viewpoints Debate: What Will it Take to Make the Use of AI/ML Tools Scalable?

  • How do you translate AI/ML technology into patient impact
    • Better treatments
    • Higher quality outcomes
    • Less adverse effect
  • Streamlining processes enterprise-wide
Speaker
Dimitris K. Agrafiotis, PhD, Chief Information Officer, Novartis Institutes for BioMedical Research (NIBR)
Speaker
Niven R. Narain, Ph.D, Co-Founder, President & CEO, BERG
Speaker
Andrew Radin, CEO & Co-Founder, twoXAR Pharmaceuticals

Confirmed Sponsors

INTERESTED IN BECOMING A SPONSOR?

Never miss an announcement